U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07944508) titled 'A Phase 1 Study of MVB-101 Administered Intraprostatically in Patients With Localized Prostate Cancer Who Are Scheduled for Radical Prostatectomy' on Nov. 05.

Brief Summary: This Phase 1, open-label, non-randomized, multicenter study will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MVB-101 administered by direct intraprostatic injection in adults with previously untreated localized adenocarcinoma of the prostate who are scheduled to undergo radical prostatectomy. Participants will receive MVB-101 once weekly for 4 weeks. Part A will use an i3+3 dose-escalation design to evaluate dose le...